Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Analyst: Optimism Around US Regulation Drives Bitcoin Price to New High

Analyst: Optimism Around US Regulation Drives Bitcoin Price to New High

金色财经金色财经2025/05/21 16:13
Show original

Bitcoin prices surged to a record high on Wednesday. The recent rebound in Bitcoin and the broader crypto market in recent weeks is attributed to regulatory positives, including a stablecoin bill proposed by the U.S. Senate after a group of Democrats dropped their opposition on Monday. This industry-supported regulatory bill will now be debated in the Senate, with a bipartisan group hoping to pass it as early as this week. Galaxy Digital founder and CEO Michael Novogratz said in an interview on Wednesday, "This is a shift from the approach of former SEC Chairman Gensler and the SEC to the Trump administration's approach, which has embraced our industry. This has unleashed 'animal spirits' (i.e., market vitality and investment enthusiasm) both domestically and internationally."

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.